UNMC Joins International Study of Gene Therapy for Ovarian Cancer


More than $17 Million Awarded in Research Grants to

UNMC

There are more than 27,000 new cases of ovarian cancer diagnosed in

America each year and 13,000 of those cases prove to be terminal.  

Ovarian cancer causes more deaths than any other reproductive organ cancer. 

The chances of survival are better if this cancer is found before it has

spread outside the ovary.

One of the grants received by the University of Nebraska Medical Center

during the first six months of 1999 enables UNMC to join researchers in

the United States, Canada, South America and Europe in a new clinical study

in the fight against ovarian cancer.

McClure Smith, M.D., professor, UNMC Department of Obstetrics/Gynecology,

is the primary investigator for the $163,950 grant.  It will be used

to research gene therapy, a new type of treatment, to help the chemotherapy

drugs fight ovarian cancer cells by replacing the missing protective gene

(p53) in the cancer cell.

“We have therapies that, when administered to ovarian cancer patients

diagnosed in the early stages, can lead to remission of the disease,” Dr.

Smith said.  “The fact is that within the last 10 years, the development

of new therapeutic agents has doubled the life expectancy for advanced

cases of ovarian cancer from 9 months to 18 months or more.

“But each time the disease comes out of remission, it is meaner and

tougher, and we have less options to offer the patient.”

The p53 gene is a protein in normal cells that controls cell division. 

In one-half of all cancers, the p53 gene has been altered.  Through

this study, Dr. Smith will attempt to replace the p53 gene in the abnormal

cells so they can respond normally again.  Patients, who are newly

diagnosed, are eligible to enroll in this study.

“We are seeking Stage 3 ovarian cancer patients, that is, patients whose

cancer is no longer totally contained within the ovaries, but has spread

throughout the abdomen,” Dr. Smith said.  “These are the patients

who, if this new ovarian cancer gene therapy protocol works, are most likely

to have the best chance of extended survival.”

Dr. Smith noted that he recently completed patient registration for

another research project utilizing a new drug designed to help chemotherapy

drugs remain effective in killing ovarian cancer cells for longer durations.

The gene therapy study grant is among more than $17 million awarded

to UNMC during the first six months of 1999 for research.  The first

quarter 1999 (January-March) research awards totaled $6.9 million. 

The second quarter 1999 (April-June) awards totaled $10.6 million.   

Funding for research during the January-June 1999 breaks down as follows:


                               

First Quarter       Second Quarter


Federal sources        $4,535,328       

$7,905,655


Industry sources        $1,289,336      

$1,186,864


State sources           

$77,020           

$317,615


Other Sources         

$976,258          $1,217,783

Kristine McVea, M.D., assistant professor, Department of Pediatrics

and Family Medicine, is primary investigator for a $50,000 award given

by the American Cancer Society.  It will be used to follow a group

of adolescent smokers for one year in order to gain an understanding of

the challenges adolescent smokers face when they attempt to stop smoking. 

The data obtained will then be used in conjunction with information from

the medical literature to develop a training program for 50 student smoking

cessation counselors.

Approximately 20 percent of AIDS patients experience severe brain disease

caused by explosive viral replication.  The National Institutes of

Health has awarded a $229,580 grant to Howard Gendelman, M.D., professor,

Department of Pathology/Microbiology, to implement new technologies and

monitor brain cell responses to determine the physiological events that

produce neural injury/death in AIDS patients.

UNMC is the only public academic health science center in the state.

Through its commitment to research, education, outreach and patient care,

UNMC has established itself as one of the country’s leading centers for

cancer research and treatment and solid organ transplantation. Nearly $31

million in research grants and contracts were awarded to UNMC scientists

during the past fiscal year. In addition, UNMC’s educational programs are

responsible for training more health professionals practicing in Nebraska

than any other institution.

DyvcCDPWnXLPeb YA C H